Kathryn Wengel - Johnson Johnson President

JNJ -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Ms. Kathryn E Wengel is the Executive Vice President, Chief Global Supply Chain Officer of the Company. She has joined the Company in 1988 as Project Engineer and Engineering Supervisor at Janssen, a subsidiary of the Company. During her tenure with the Company, she has held a variety of strategic leadership and executive positions across the global enterprise, in roles within operations, quality, engineering, new products, information technology, and other technical and business functions. In 2010, Ms. Wengel became the first Chief Quality Officer of the Company. In 2014, she was promoted to Vice President, Johnson Johnson Supply Chain. In July 2018, she was promoted to Executive Vice President, Chief Global Supply Chain Officer, and became a member of the Executive Committee.
Age: 52  President Since 2018      
732-524-0400  http://www.jnj.com

Kathryn Wengel Latest Insider Activity

Management Efficiency

The company has Return on Asset of 0.12 % which means that on every $100 spent on asset it made $0.12 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.22 % implying that it generated $0.22 on every 100 dollars invested.
The company has 30.43 B in debt with debt to equity (D/E) ratio of 50.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Johnson Johnson has Current Ratio of 1.3 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Adele AmbroseMerck Company
Diana BrainardGilead Sciences
Michael RosenblattMerck Company
James FordGlaxoSmithKline PLC
CDavid NicholsonAllergan Plc
Susan MahonyEli Lilly And Company
John McHutchisonGilead Sciences
Myles ONeillEli Lilly And Company
Charles HillPfizer
Jyoti MehraGilead Sciences
Jeffrey SimmonsEli Lilly And Company
Matthew WalshAllergan Plc
Leigh PuseyEli Lilly And Company
Dawn RogersPfizer
Abbas HussainGlaxoSmithKline PLC
Adam SchechterMerck Company
Karen SantiagoBristol Myers Squibb Company
Phil ThomsonGlaxoSmithKline PLC
Joshua SmileyEli Lilly And Company
Andrew DickinsonGilead Sciences
Hal BarronGlaxoSmithKline PLC

Entity Summary

Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 135100 people.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson & Johnson Plaza and employs 135,100 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent Director
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
D Davis, Independent Director
Hubert Joly, Director
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Ian Davis, Independent Director
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Susan Lindquist, Independent Director
Mark Weinberger, Director

Stock Performance Indicators

Current Sentiment - JNJ

Johnson Johnson Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Johnson Johnson. What is your judgment towards investing in Johnson Johnson? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try World Markets Correlation module to find global opportunities by holding instruments from different markets.
Search macroaxis.com